Ceftriaxone Sodium

Cephalosporin antibiotic Third-generation cephalosporin

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog IV or IM 25-50 mg/kg q12h or q24h Duration: 7-14 days depending on infection
Notes: For severe infections, use higher end and q12h. Not FDA-approved for dogs; extra-label use.
Cat IV or IM 25-50 mg/kg q12h or q24h Duration: 7-14 days
Notes: Use with caution in cats with renal impairment. Not FDA-approved.
Horse IV or IM 25-50 mg/kg q12h Duration: 5-10 days
Notes: IM injections may cause pain and tissue irritation. Not FDA-approved for horses.
Cattle IV or IM 20-50 mg/kg q24h Duration: 3-5 days
Notes: Extra-label use; ceftiofur is preferred. Withdrawal times must be observed.
Small Ruminants (sheep/goats) IV or IM 20-50 mg/kg q24h Duration: 3-5 days
Notes: Extra-label use; not approved. Observe withdrawal times.
Rabbit IV or IM 25-50 mg/kg q12h Duration: 7-14 days
Notes: Limited data; use with caution. May cause GI disturbances.
Birds/Poultry IM or IV 50-100 mg/kg q12h Duration: 5-7 days
Notes: Not approved; extra-label use. May cause nephrotoxicity in birds.
Exotic/Other IV or IM Varies widely; consult a specialist Varies Duration: Varies
Notes: Dosing is extrapolated; use with caution.

Clinical Indications & Species Uses

General Indications
  • Treatment of infections caused by susceptible Gram-positive and Gram-negative bacteria, including those producing beta-lactamases. Often reserved for serious infections when other antibiotics fail.
Dog (Canine)
  • Treatment of bacterial infections caused by susceptible organisms, including skin and soft tissue infections, urinary tract infections, respiratory tract infections, septicemia, and Lyme disease (as an alternative to doxycycline).
Cat (Feline)
  • Treatment of bacterial infections such as urinary tract infections, respiratory infections, skin infections, and septicemia.

Pharmacology & Mechanism of Action

Drug Class: Cephalosporin antibiotic | Pharmacological Group: Third-generation cephalosporin

Mechanism of Action: Ceftriaxone is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to disruption of peptidoglycan cross-linking and ultimately cell lysis. It is bactericidal and has enhanced activity against Gram-negative bacteria due to its stability against many beta-lactamases.

Pharmacodynamics: Ceftriaxone exhibits time-dependent killing with a post-antibiotic effect (PAE) against Gram-negative bacteria. Its efficacy correlates with the time the free drug concentration exceeds the minimum inhibitory concentration (MIC) for the pathogen. It has a broad spectrum including many Enterobacteriaceae, Streptococcus spp., and some anaerobes, but lacks activity against methicillin-resistant staphylococci and enterococci.

⚑ Pharmacokinetics Summary

Absorption: Ceftriaxone is not absorbed orally; it must be administered parenterally (IV or IM). After IM injection, absorption is rapid and complete, with peak plasma concentrations achieved within 1-2 hours.
Distribution: Ceftriaxone is widely distributed into body tissues and fluids, including cerebrospinal fluid (especially with inflamed meninges), pleural fluid, synovial fluid, and peritoneal fluid. It crosses the placenta and is excreted in milk. Protein binding is high (85-95%) and saturable.
Metabolism: Ceftriaxone undergoes minimal hepatic metabolism; it is not significantly biotransformed.
Excretion: Ceftriaxone is eliminated primarily via renal excretion (approximately 33-67% unchanged in urine) and the remainder via biliary secretion into the feces. In animals with renal impairment, biliary excretion increases.
Half-Life: Dog: approximately 1-2 hours; Cat: approximately 1.5-3 hours; Horse: approximately 1-2 hours; Cattle: approximately 1-2 hours; Humans: 6-8 hours (not typical for veterinary use).
Bioavailability: Oral bioavailability is negligible; IM bioavailability is nearly 100%.
Protein Binding: 85-95% in most species, but can be lower in some animals (e.g., 60-70% in dogs).

Available Formulations & Strengths

Injectable Solution (powder for reconstitution) 250 mg, 500 mg, 1 g, 2 g vials (IV or IM)

Contraindications & Clinical Warnings

Contraindications:
  • Known hypersensitivity to ceftriaxone, other cephalosporins, or beta-lactam antibiotics.
  • Use in patients with a history of anaphylactic reactions to penicillins (cross-reactivity may occur).
  • Do not administer to neonates with hyperbilirubinemia (risk of bilirubin encephalopathy due to displacement from albumin).
Warnings & Clinical Precautions:
  • Use with caution in animals with renal or hepatic impairment; dose adjustment may be necessary.
  • Prolonged use may result in superinfection with resistant organisms (e.g., Clostridium difficile).
  • IM injections can cause pain, swelling, and tissue necrosis; administer deep IM and rotate sites.
  • In food animals, extra-label use is prohibited in some countries; check regulations.
  • May cause hemolytic anemia in some species (rare).
  • Use in pregnant or lactating animals only if clearly needed; safety not fully established.

Adverse Effects & Reactions

Common:

  • Pain at injection site
  • Swelling at injection site
  • Gastrointestinal upset (vomiting, diarrhea)
  • Hypersensitivity reactions (rash, fever)

Serious / Severe:

  • Anaphylaxis
  • Hemolytic anemia
  • Bone marrow suppression (neutropenia, thrombocytopenia)
  • Nephrotoxicity (especially in dehydrated animals)
  • Hepatotoxicity (elevated liver enzymes)
  • Neurological signs (seizures) in overdose or renal impairment

Rare:

  • Pseudomembranous colitis
  • Crystalluria
  • Biliary sludging (in animals with biliary stasis)
  • Superinfection with resistant organisms

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Aminoglycosides (e.g., gentamicin) Additive nephrotoxicity; increased risk of renal damage. High
Loop diuretics (e.g., furosemide) Increased risk of nephrotoxicity. Moderate
Probenecid Decreases renal excretion of ceftriaxone, increasing plasma levels and risk of toxicity. Moderate
Warfarin and other anticoagulants May enhance anticoagulant effect; monitor coagulation parameters. Moderate
Calcium-containing solutions (e.g., Ringer's lactate) Risk of precipitation when mixed in IV lines; do not administer simultaneously via Y-site. High

Overdose & Toxicity Management

Signs of Toxicity:

  • Seizures
  • Neurological signs (tremors, ataxia)
  • Nausea and vomiting
  • Diarrhea
  • Renal failure (with high doses)

Emergency Treatment Protocol: There is no specific antidote. Treatment is symptomatic and supportive. Discontinue the drug, provide fluid therapy to maintain renal perfusion, and consider anticonvulsants (e.g., diazepam) for seizures. Hemodialysis may be considered in severe cases, but it is not commonly performed in veterinary patients.

Food Animal Withdrawal Times

πŸ₯© Meat: 14 daysπŸ₯› Milk: 4 days

Withdrawal times are not established for ceftriaxone in food animals; extra-label use requires extended withdrawal periods. Consult regulatory guidelines. For cattle, a meat withdrawal of at least 14 days and milk withdrawal of 4 days is often recommended, but these are not official.

Storage, Handling & Regulatory Information

Storage Temperature: Store powder at controlled room temperature (20-25Β°C). Reconstituted solution is stable for 24 hours at room temperature and 72 hours under refrigeration (2-8Β°C).

Light Sensitivity: Light-sensitive β€” protect from direct exposure.

Handling & Special Conditions: Protect from light. Do not freeze reconstituted solution. Discard unused portions after stability period.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not approved for veterinary use in the US; approved for human use. No veterinary-labeled products exist.

Extra-Label (Off-Label) Use: In the US, extra-label use of ceftriaxone in food animals is prohibited by the FDA (as of 2012) due to its importance in human medicine. In companion animals, extra-label use is permitted under AMDUCA with appropriate veterinary oversight. In the EU, similar restrictions apply.

Clinical Pearls & Practice Notes

πŸ’‘ Clinical Insights: Ceftriaxone is a broad-spectrum third-generation cephalosporin with excellent activity against many Gram-negative bacteria, including those producing beta-lactamases. It is often reserved for serious infections such as septicemia, meningitis, and complicated urinary tract infections when other antibiotics are ineffective. Due to its high protein binding and long half-life in some species, it can be administered once daily in some cases. However, its use in veterinary medicine is limited by cost, lack of approved formulations, and the need for parenteral administration. In food animals, its use is restricted due to public health concerns about antimicrobial resistance. For most veterinary infections, other cephalosporins like ceftiofur or cefovecin are preferred. Always perform culture and sensitivity testing when possible, and adhere to prudent use guidelines to minimize resistance development.

References & Literature

  • πŸ“š Plumb's Veterinary Drug Handbook
  • πŸ“š Papich Veterinary Pharmacology and Therapeutics
  • πŸ“š Compendium of Veterinary Products (CVP)